AIxCrypto Holdings (AIXC) Registration filing summary

Company overview and business model

• Early clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, with lead program QN-302 in Phase 1a clinical trials and a preclinical Pan-RAS program targeting oncogene protein interactions.

• Recent strategic investment in Marizyme, Inc. for commercialization of DuraGraft, with royalty rights on future sales, and minority interest in NanoSynex, an antimicrobial diagnostics company.

• Sold former diagnostics business in July 2023 to focus exclusively on therapeutics.

Financial performance and metrics

• As of June 30, 2024, cash balance was $118,685, with a stockholders' deficit of $(4.3) million and recurring losses from operations.

• Net proceeds from the offering are estimated up to $3.7 million, with immediate dilution of $0.22 per share to new investors at an assumed offering price of $0.20 per share.

• Working capital deficiency and recurring losses raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds intended for operations, clinical and preclinical studies, accelerated payment of a $2 million Senior Note, potential expansion with Marizyme, general working capital, and possible acquisitions.

• If net proceeds are less than $2 million, all proceeds will be allocated to the Senior Note repayment.